Back

Moderna shares rise on melanoma vaccine news as CEO faces oncology question

Verifying
  • Moderna’s share price rose after positive news about its melanoma vaccine.
  • August brought positive news on Moderna’s vaccine to prevent melanoma recurrence.
  • Cynthia Koons asked CEO Stéphane Bancel about Moderna’s delayed oncology entry yesterday.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.